An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006)

• Status: Completed
• Trial end date: 2008-04-01
• Target enrollment: 0
• Participant gender: All

Summary

A study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-0941 in Type 2 diabetics being treated with basal insulin.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Insulin; Insulin Glargine; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Male or female (of non-childbearing potential) between 18 to 70 years of age

• Diagnosed with Type 2 Diabetes and currently being treated with basal insulin

• Smokers may participate, but they are limited to 10 cigarettes per day while at the clinic and must follow clinic smoking rules

Exclusion Criteria:

• History of Type 1 diabetes

• Treated with peroxisome proliferator-activated receptor (PPAR) agonists within 12 weeks prior to study start

• History of severe hypoglycemia

• Allergic to insulin